The results showed the efficacy of the Cooled ThermoCath (CTC) microwave catheter is durable for at least five years and the freedom from additional minimally invasive or surgical procedures is 90%. The data from the study showed clinically significant improvement from baseline of the three major benign prostatic hyperplasia (BPH) evaluation criteria – urinary flow rate, symptom improvement, and quality of life at the five-year follow-up.
CTC is used exclusively with the Urologix CoolWave or Targis control units. The therapy is delivered in the comfortable setting of a physician’s office with a treatment time of less than 30 minutes.
Alan Partin, chairman of the James Buchanan Brady Urological Institute at the Johns Hopkins Medical Institution, said: “We believe these long term clinical results will aid physicians and patients in their decision making when weighing treatment options.”